Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer

Lianxi Song; Liang Zeng; Huan Yan; Qinqin Xu; Qing Xia; Jian Lei; Xiaoyan Chen; Xiaoping Hu; Zhan Wang; Hong Liu; Nong Yang; Yongchang Zhang

doi:10.1038/s43856-022-00206-4

Communications Medicine (Nov 2022)

Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer

Lianxi Song,
Liang Zeng,
Huan Yan,
Qinqin Xu,
Qing Xia,
Jian Lei,
Xiaoyan Chen,
Xiaoping Hu,
Zhan Wang,
Hong Liu,
Nong Yang,
Yongchang Zhang

Affiliations

Lianxi Song: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Liang Zeng: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Huan Yan: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Qinqin Xu: Department of Medical Oncology, Qinghai Provincial People’s Hospital
Qing Xia: State Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Department of Oncology, Shanghai Jiao Tong University School of Medicine
Jian Lei: Department of Pathology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Xiaoyan Chen: Department of Pathology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Xiaoping Hu: Department of Pathology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Zhan Wang: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Hong Liu: Department of Dermatology, Xiangya Hospital, Central South University
Nong Yang: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Yongchang Zhang: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

DOI: https://doi.org/10.1038/s43856-022-00206-4
Journal volume & issue: Vol. 2, no. 1
pp. 1 – 9

Abstract

Read online

Song, Zeng, Yan et al. validate the E1L3N monoclonal antibody for the detection of PD-L1 in NSCLC samples. The authors show that PD-L1 scores assessed with E1L3N are concordant with the 22C3 assay and are associated with response to first-line pembrolizumab monotherapy.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal